No Data
No Data
Green Bamboo Biotech -B (02480.HK) plans to hold a board of directors meeting on August 21 to approve its mid-year performance.
Chlorophyll Biology - B (02480.HK) announced on August 9 that the company will hold a board of directors meeting on Wednesday, August 21, 2024 to (including) consider and approve the unaudited comprehensive mid-term performance of the company and its subsidiaries for the six months ending June 30, 2024, and to consider the proposal of distributing mid-term dividends (if any).
Luzhu Bio-B (02480) bought back 3400 shares on July 16th.
Green Bamboo Biotech-B (02480) announced that it will spend HKD 0.083 million to repurchase 34... on July 16, 2024.
On July 15th, Luye Pharma Group Ltd-B (02480.HK) spent HKD 28.174 million to repurchase 1.1544 million shares.
On July 15th, Green Bamboo Biological-B (02480.HK) announced the repurchase of 1.1544 million shares for HKD 28.174 million.
On July 12th, Green Bamboo Biotech -B (02480.HK) spent 6.63 million Hong Kong dollars to repurchase 0.278 million shares.
On July 12th, Gelonhui reported that Lvshe Biology-B (02480.HK) spent 6.63 million Hong Kong dollars to buy back 0.278 million shares on July 12, 2024, with a buyback price of 23.45-24.05 Hong Kong dollars per share.
With a daily trading volume of only 3200 shares, Green Bamboo Biopharmaceutical-B (02480), which holds a heavyweight vaccine, has fallen into a liquidity crisis.
The earliest time for Lvzhushengwu to introduce its first commercial product will be the end of next year, and the lack of a commercial product as a valuation anchor means that the company's stock price is susceptible to market fluctuations until the R&D milestones are clearly identified to strengthen its market research and valuation.
LUZHU BIOTECH-B: Annual Report 2023
No Data